Long-term ranibizumab beneficial for macular edema

October 11, 2012
Long-term ranibizumab beneficial for macular edema
Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness and improved best-corrected visual acuity, according to research published online Oct. 8 in the Archives of Ophthalmology.

(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity (BCVA), according to research published online Oct. 8 in the Archives of Ophthalmology.

Diana V. Do, M.D., of the Wilmer Eye Institute at the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a follow-up of outcomes from the for Edema of the Macula in Diabetes study from year two (month 24) to year three (month 36) to assess the benefit of increased follow-up. Participants included 28 patients who received ranibizumab (0.5 mg monthly if FTH was 250 µm or greater), 22 patients who received laser treatment, and 24 patients who received ranibizumab plus laser treatment.

The researchers found that ranibizumab-treated patients displayed a significant mean BCVA improvement of 10.3 letters at month 36 compared with only 7.2 letters at month 24. Mean FTH was reduced from 352 to 282 µm at months 36 and 24, respectively. No statistically significant difference was observed for BCVA and FTH between the ranibizumab-plus-laser group and the laser-only group. However, ranibizumab-treated patients required significantly more injections than laser-treated patients (5.4 versus 2.3 injections), but not significantly more than the ranibizumab-plus-laser group.

"Long-term visual outcomes for treatment of with ranibizumab are excellent, but many patients require frequent injections to optimally control edema and maximize vision," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Study suggests treatments for 'wet' AMD keep elderly drivers behind the wheel

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Study suggests treatments for 'wet' AMD keep elderly drivers behind the wheel

October 2, 2012
The advanced neovascular, or "wet," form of age-related macular degeneration (AMD), left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges. But ...

Study reports two-year outcomes of diabetic macular edema treatment

April 9, 2012
A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that ...

Study estimates potential for ranibizumab to prevent blindness from age-related macular degeneration

June 13, 2011
A computer modeling study suggests that administering the drug ranibizumab is associated with reducing the magnitude of legal blindness and visual impairment caused by age-related macular degeneration in non-Hispanic white ...

Mayo Clinic detective work shows possible side effect in macular degeneration drug

October 24, 2011
Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure ...

Recommended for you

Newly published research provides new insight into how diabetes leads to retinopathy

December 7, 2017
An international team of scientists led by Professor Ingrid Fleming of Goethe University, Frankfurt, Germany, and including Professor Bruce Hammock of the University of California, Davis, provides new insight into the mechanism ...

Researchers use breakthrough technology to understand eclipse eye damage

December 7, 2017
In a first-of-its-kind study, Mount Sinai researchers are using adaptive optics (AO) to analyze retinal eye damage from the August solar eclipse on a cellular level. The research could help doctors develop a deeper understanding ...

Combating eye injuries with a reversible superglue seal

December 6, 2017
When a soldier sustains a traumatic eye injury on the battlefield, any delay in treatment may lead to permanent vision loss. With medical facilities potentially far away and no existing tools to prevent deterioration, medics ...

Trigger for most common form of vision loss discovered

November 27, 2017
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the ...

Scientists engineer drug delivery device that treats glaucoma directly inside the eye

November 23, 2017
Glaucoma, which affects over 60 million people worldwide, can seem easy to treat: medicated eye drops can be used to ease the buildup of fluid in the eye that underlies the condition. If glaucoma is caught early, eye drops ...

Research reveals biological mechanism of a leading cause of childhood blindness

November 16, 2017
Scientists at the Virginia Tech Carilion Research Institute (VTCRI) have revealed the pathology of cells and structures stricken by optic nerve hypoplasia, a leading cause of childhood blindness in developed nations.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.